Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort-Reference-Cited by-同舟云学术

Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort

Published:2016-06-21 Issue:15 Volume:76 Page:1409-1419
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Brooks James D.¹,Wei Wei²,Pollack Jonathan R.³,West Robert B.³,Shin Jun Ho⁴,Sunwoo John B.⁴,Hawley Sarah J.⁵,Auman Heidi⁵,Newcomb Lisa F.⁶,Simko Jeff⁷,Hurtado-Coll Antonio⁸,Troyer Dean A.⁹¹⁰,Carroll Peter R.¹¹,Gleave Martin E.⁸,Lin Daniel W.⁶,Nelson Peter S.¹²,Thompson Ian M.¹³,True Lawrence D.¹⁴,McKenney Jesse K.¹⁵,Feng Ziding²,Fazli Ladan⁸

Affiliation:

1. Department of Urology; Stanford University; Stanford California

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Pathology; Stanford University; Stanford California

4. Department of Otolaryngology-Head and Neck Surgery; Stanford University; Stanford California

5. Canary Foundation; Canary Center at Stanford; Palo Alto California

6. Department of Urology; University of Washington Medical Center; Seattle Washington

7. Department of Pathology; University of California San Francisco; San Francisco California

8. Department of Urologic Sciences and Vancouver Prostate Centre; Vancouver British Columbia Canada

9. Department of Pathology; University of Texas Health Science Center at San Antonio; San Antonio Texas

10. Eastern Virginia Medical School; Pathology and Microbiology and Molecular Biology; Norfolk Virginia

11. Department of Urology; University of California San Francisco; San Francisco California

12. Division of Human Biology; Fred Hutchinson Cancer Research Center; Seattle Washington

13. Department of Urology; University of Texas Health Science Center at San Antonio; San Antonio Texas

14. Department of Pathology; University of Washington Medical Center; Seattle Washington

15. Department of Pathology; Cleveland Clinic; Cleveland Ohio

Funder

Canary Foundation

Burroughs Wellcome Fund

Department of Defense

National Cancer Institute

NCI Early Detection Research Network

Publisher

Wiley

Subject

Urology,Oncology

Reference37 articles.

1. Screening for prostate cancer: U.S. preventive services task force recommendation statement;Ann Intern Med,2008

2. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials;Saquib;Int J Epidemiol,2015

3. Mortality results from a randomized prostate-cancer screening trial;Andriole;N Engl J Med,2009

4. Prostate-cancer mortality at 11 years of follow-up;Schroder;N Engl J Med,2012

5. Managing localized prostate cancer in the era of prostate-specific antigen screening;Brooks;Cancer,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zinc-alpha-2-glycoprotein Secreted by Triple-Negative Breast Cancer Promotes Peritumoral Fibrosis;Cancer Research Communications;2024-07-01

2. AZGP1 deficiency promotes angiogenesis in prostate cancer;Journal of Translational Medicine;2024-04-24

3. Zinc Alpha-2-Glycoprotein (ZAG/AZGP1) secreted by triple-negative breast cancer promotes tumor microenvironment fibrosis;2024-03-07

4. AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification;Research;2023-01

5. AZGP1 Up-Regulation is a Potential Target for Andrographolide Reversing Radioresistance of Colorectal Cancer;Pharmacogenomics and Personalized Medicine;2022-12